| Stage | PH | % of rev | HLIO | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $5.8B | 100.00% | $232M | 100.00% | PH ×24.82 |
| Gross profit | $2.2B | 39.04% | $80M | 34.58% | PH +4.5pp |
| Operating income | $1.4B | 23.86% | $33M | 14.01% | PH +9.8pp |
| Pre-tax income | $1.3B | 23.28% | $28M | 12.12% | PH +11.2pp |
| Net income | $1.1B | 18.97% | $22M | 9.44% | PH +9.5pp |
| Stage | PH | HLIO | Gap · A − B |
|---|---|---|---|
| Revenue | $5.8B100.00% | $232M100.00% | PH ×24.82 |
| Gross profit | 39.04%$2.2B | 34.58%$80M | PH +4.5pp |
| Operating income | 23.86%$1.4B | 14.01%$33M | PH +9.8pp |
| Pre-tax income | 23.28%$1.3B | 12.12%$28M | PH +11.2pp |
| Net income |
| 18.97%$1.1B |
| 9.44%$22M |
| PH +9.5pp |
No disclosed counterparties: HLIO.
None